This report provides a brief overview of targets of interest from MJFF’s portfolio. Profiles for emerging and advanced targets provide a summary of the current status of the target as it relates to therapeutic development, how it is connected to Parkinson's Disease, and what MJFF’s investments have been up to this point. Novel targets at an earlier exploratory stage are listed in a table as the available information may be limited. As targets advance from novel to emerging, and remain of interest, profiles will be built out to contain additional details. This report is not comprehensive of every potential target being explored today but represents those recently supported by MJFF that have been identified by research staff as important to monitor and build awareness around. There are additional advanced clinical targets within the MJFF portfolio that are not included here but can be found in MJFF’s Clinical Pipeline Report and Biomarker Report. Although not currently in scope, there is the possibility of expanding to targets outside of MJFF’s portfolio in future iterations. Statements and categorizations made throughout may be subjective and based on MJFF expertise and opinion. All information included in this report is publicly available and is intended to be used as a resource for researchers and investors evaluating opportunities and/or seeking new projects.

March 2023 Edition